
PharmAbcine Inc.
- Home
- Companies
- PharmAbcine Inc.
- Products
- PharmAbcine - Model PMC-309 - ...

PharmAbcine - Model PMC-309 - Engineered Monoclonal Antibody
FromPharmAbcine Inc.
PMC-309 is an engineered monoclonal antibody that targets the negative immune checkpoint human VISTA (V-domain Ig suppressor of T cell activation). It indirectly promotes T cells` immune responses by inhibiting VISTA-expressing immunosuppressive cells such as MDSCs (Myeloid-Derived Suppressor Cells) which suppress T cell inactivation and proliferation.
Most popular related searches
monoclonal antibody
T-cell
immune checkpoints
immune checkpoint
immune response
solid tumor
immunosuppression
immune cell
- Solid tumors
- The molecule`s mechanism and preclinical efficacies have been confirmed in human VISTA-KI mouse model. PharmAbcine initiated the GLP-tox study of PMC-309 in 2Q21 and expects an IND filing in 2Q22.